The blood–brain barriers: novel nanocarriers for central nervous system diseases
Journal of Nanobiotechnology,
Journal Year:
2025,
Volume and Issue:
23(1)
Published: Feb. 26, 2025
Abstract
The
central
nervous
system
(CNS)
diseases
are
major
contributors
to
death
and
disability
worldwide.
However,
the
blood–brain
barrier
(BBB)
often
prevents
drugs
intended
for
CNS
from
effectively
crossing
into
brain
parenchyma
deliver
their
therapeutic
effects.
is
a
semi-permeable
with
high
selectivity.
BBB
primarily
manages
transport
of
substances
between
blood
CNS.
To
enhance
drug
delivery
disease
treatment,
various
brain-based
strategies
overcoming
have
been
developed.
Among
them,
nanoparticles
(NPs)
emphasized
due
multiple
excellent
properties.
This
review
starts
an
overview
BBB’s
anatomical
structure
physiological
roles,
then
explores
mechanisms,
both
endogenous
exogenous,
that
facilitate
NP
passage
across
BBB.
text
also
delves
how
nanoparticles'
shape,
charge,
size,
surface
ligands
affect
ability
cross
offers
different
nanoparticle
classifications.
concludes
examination
current
challenges
in
utilizing
nanomaterials
discusses
corresponding
directions
solutions.
aims
propose
innovative
diagnostic
approaches
design
more
effective
Graphical
abstract
Language: Английский
Decoding Neurodegeneration: A Review of Molecular Mechanisms and Therapeutic Advances in Alzheimer’s, Parkinson’s, and ALS
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(23), P. 12613 - 12613
Published: Nov. 24, 2024
Neurodegenerative
diseases,
such
as
Alzheimer's,
Parkinson's,
ALS,
and
Huntington's,
remain
formidable
challenges
in
medicine,
with
their
relentless
progression
limited
therapeutic
options.
These
diseases
arise
from
a
web
of
molecular
disturbances-misfolded
proteins,
chronic
neuroinflammation,
mitochondrial
dysfunction,
genetic
mutations-that
slowly
dismantle
neuronal
integrity.
Yet,
recent
scientific
breakthroughs
are
opening
new
paths
to
intervene
these
once-intractable
conditions.
This
review
synthesizes
the
latest
insights
into
underlying
dynamics
neurodegeneration,
revealing
how
intertwined
pathways
drive
course
diseases.
With
an
eye
on
most
promising
advances,
we
explore
innovative
therapies
emerging
cutting-edge
research:
nanotechnology-based
drug
delivery
systems
capable
navigating
blood-brain
barrier,
gene-editing
tools
like
CRISPR
designed
correct
harmful
variants,
stem
cell
strategies
that
not
only
replace
lost
neurons
but
foster
neuroprotective
environments.
Pharmacogenomics
is
reshaping
treatment
personalization,
enabling
tailored
align
individual
profiles,
while
diagnostics
biomarkers
ushering
era
early,
precise
disease
detection.
Furthermore,
novel
perspectives
gut-brain
axis
sparking
interest
mounting
evidence
suggests
microbiome
modulation
may
play
role
reducing
neuroinflammatory
responses
linked
neurodegenerative
progression.
Taken
together,
advances
signal
shift
toward
comprehensive,
personalized
approach
could
transform
care.
By
integrating
techniques,
this
offers
forward-looking
perspective
future
where
treatments
aim
just
manage
symptoms
fundamentally
alter
progression,
presenting
renewed
hope
for
improved
patient
outcomes.
Language: Английский
Nanotechnology in Parkinson’s Disease: overcoming drug delivery challenges and enhancing therapeutic outcomes
Irfan Ali,
No information about this author
Mohammad Adil,
No information about this author
Mohammad Imran
No information about this author
et al.
Drug Delivery and Translational Research,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 29, 2025
Language: Английский
Diagnosis of neurological and non-neurological disorders via bimodal/multimodal imaging with lanthanide based nanoparticles
Coordination Chemistry Reviews,
Journal Year:
2025,
Volume and Issue:
532, P. 216527 - 216527
Published: Feb. 18, 2025
Language: Английский
The Art of Neuroregeneration De Novo and In Situ
Advances in experimental medicine and biology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 1, 2025
Language: Английский
A comprehensive review on lipid-based nanoparticles via nose to brain targeting as a novel approach
Huma Hameed,
No information about this author
Saleha Faheem,
No information about this author
Komel Younas
No information about this author
et al.
Journal of Microencapsulation,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 34
Published: Sept. 17, 2024
The
central
nervous
system
(CNS)
has
been
a
chief
concern
for
millions
of
people
worldwide,
and
many
therapeutic
medications
are
unable
to
penetrate
the
blood-brain
barrier.
Advancements
in
nanotechnology
have
enabled
safe,
effective,
precise
delivery
towards
specific
brain
regions
by
utilising
nose-to-brain
targeting
route.
This
method
reduces
adverse
effects,
increases
medication
bioavailability,
facilitates
mucociliary
clearance
while
promoting
accumulation
drug
targeted
region.
Recent
developments
lipid-based
nanoparticles,
instance
solid
lipid
nanoparticles
(SLNs),
liposomes,
nanoemulsions,
nano-structured
carriers
explored.
SLNs
currently
most
promising
carrier
because
their
capability
transporting
drugs
across
barrier
at
intended
site.
approach
offers
higher
efficacy,
controlled
delivery,
target
specificity,
longer
circulation
time,
reduction
toxicity
through
biomimetic
mechanism.
Language: Английский